# Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery

> **NCT05950152** · PHASE2 · UNKNOWN · sponsor: **Beijing Tide Pharmaceutical Co., Ltd** · enrollment: 108 (estimated)

## Conditions studied

- Pain, Post-operative

## Interventions

- **DRUG:** Meloxicam Injection 30mg
- **DRUG:** Meloxicam Injection 60mg
- **DRUG:** Nacl 0.9%

## Key facts

- **NCT ID:** NCT05950152
- **Lead sponsor:** Beijing Tide Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07
- **Primary completion:** 2023-12
- **Final completion:** 2024-02
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05950152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05950152, "Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05950152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*